Initial bids for the pharmaceutical company are expected as early as this week. Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY)and Gilead Sciences (GILD) could make possible bids, according to reports. Amgen is seen as the most likely buyer, according to sources cited in a Reuters article, after its $120 per share offer was rejected by Onyx (ONYX) last month. Amgen shares fell 0.4% to 104.05.
- Health Care Industry
- Gilead Sciences